Covid-19 Impact on Immuno-oncology Drugs Market, Global Research Reports 2020-2021

June 2020 | 100 pages | ID: CEC31A40564FEN
QYResearch

Abstracts

This report covers market size and forecasts of Immuno-oncology Drugs, including the following market information:

• Global Immuno-oncology Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
• Global Immuno-oncology Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
• Global Immuno-oncology Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
• Global Immuno-oncology Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players

Major competitors identified in this market include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte, etc.

Based on the Region:

• Asia-Pacific (China, Japan, South Korea, India and ASEAN)
• North America (US and Canada)
• Europe (Germany, France, UK and Italy)
• Rest of World (Latin America, Middle East & Africa)

Based on the Type:

• Immune Checkpoint Inhibitors
• Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• CAR-T Cell Therapy

Based on the Application:

• Hospitals
• Pharmacies
• Online Pharmacies

Contents

1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
  1.4.1 Research Process
  1.4.2 Data Triangulation
  1.4.3 Research Approach
  1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
  1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
  1.5.2 Covid-19 Impact: Commodity Prices Indices
  1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Immuno-oncology Drugs Industry
1.7 COVID-19 Impact: Immuno-oncology Drugs Market Trends

2 GLOBAL IMMUNO-ONCOLOGY DRUGS QUARTERLY MARKET SIZE ANALYSIS

2.1 Immuno-oncology Drugs Business Impact Assessment - COVID-19
  2.1.1 Global Immuno-oncology Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  2.1.2 Global Immuno-oncology Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Immuno-oncology Drugs Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  2.3.1 Drivers
  2.3.2 Restraints
  2.3.3 Opportunities
  2.3.4 Challenges

3 QUARTERLY COMPETITIVE ASSESSMENT, 2020

3.1 Global Immuno-oncology Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Immuno-oncology Drugs Factory Price by Manufacturers
3.3 Location of Key Manufacturers Immuno-oncology Drugs Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Immuno-oncology Drugs Market
3.5 Key Manufacturers Immuno-oncology Drugs Product Offered
3.6 Mergers & Acquisitions, Expansion Plans

4 IMPACT OF COVID-19 ON IMMUNO-ONCOLOGY DRUGS SEGMENTS, BY TYPE

4.1 Introduction
  1.4.1 Immune Checkpoint Inhibitors
  1.4.2 Monoclonal Antibodies
  1.4.3 Cytokine-Based Immunotherapy
  1.4.4 Cancer Vaccines
  1.4.5 CAR-T Cell Therapy
4.2 By Type, Global Immuno-oncology Drugs Market Size, 2019-2021
  4.2.1 By Type, Global Immuno-oncology Drugs Market Size by Type, 2020-2021
  4.2.2 By Type, Global Immuno-oncology Drugs Price, 2020-2021

5 IMPACT OF COVID-19 ON IMMUNO-ONCOLOGY DRUGS SEGMENTS, BY APPLICATION

5.1 Overview
  5.5.1 Hospitals
  5.5.2 Pharmacies
  5.5.3 Online Pharmacies
5.2 By Application, Global Immuno-oncology Drugs Market Size, 2019-2021
  5.2.1 By Application, Global Immuno-oncology Drugs Market Size by Application, 2019-2021
  5.2.2 By Application, Global Immuno-oncology Drugs Price, 2020-2021

6 GEOGRAPHIC ANALYSIS

6.1 Introduction
6.2 North America
  6.2.1 Macroeconomic Indicators of US
  6.2.2 US
  6.2.3 Canada
6.3 Europe
  6.3.1 Macroeconomic Indicators of Europe
  6.3.2 Germany
  6.3.3 France
  6.3.4 UK
  6.3.5 Italy
6.4 Asia-Pacific
  6.4.1 Macroeconomic Indicators of Asia-Pacific
  6.4.2 China
  6.4.3 Japan
  6.4.4 South Korea
  6.4.5 India
  6.4.6 ASEAN
6.5 Rest of World
  6.5.1 Latin America
  6.5.2 Middle East and Africa

7 COMPANY PROFILES

7.1 Amgen, Inc
  7.1.1 Amgen, Inc Business Overview
  7.1.2 Amgen, Inc Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.1.3 Amgen, Inc Immuno-oncology Drugs Product Introduction
  7.1.4 Amgen, Inc Response to COVID-19 and Related Developments
7.2 AstraZeneca, Plc
  7.2.1 AstraZeneca, Plc Business Overview
  7.2.2 AstraZeneca, Plc Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.2.3 AstraZeneca, Plc Immuno-oncology Drugs Product Introduction
  7.2.4 AstraZeneca, Plc Response to COVID-19 and Related Developments
7.3 Bristol-Myers Squibb
  7.3.1 Bristol-Myers Squibb Business Overview
  7.3.2 Bristol-Myers Squibb Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Product Introduction
  7.3.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
7.4 Celgene Corporation
  7.4.1 Celgene Corporation Business Overview
  7.4.2 Celgene Corporation Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.4.3 Celgene Corporation Immuno-oncology Drugs Product Introduction
  7.4.4 Celgene Corporation Response to COVID-19 and Related Developments
7.5 Eli Lilly and Company
  7.5.1 Eli Lilly and Company Business Overview
  7.5.2 Eli Lilly and Company Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.5.3 Eli Lilly and Company Immuno-oncology Drugs Product Introduction
  7.5.4 Eli Lilly and Company Response to COVID-19 and Related Developments
7.6 Merck & Co.
  7.6.1 Merck & Co. Business Overview
  7.6.2 Merck & Co. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.6.3 Merck & Co. Immuno-oncology Drugs Product Introduction
  7.6.4 Merck & Co. Response to COVID-19 and Related Developments
7.7 Hoffmann-La Roche AG
  7.7.1 Hoffmann-La Roche AG Business Overview
  7.7.2 Hoffmann-La Roche AG Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Product Introduction
  7.7.4 Hoffmann-La Roche AG Response to COVID-19 and Related Developments
7.8 Johnson & Johnson
  7.8.1 Johnson & Johnson Business Overview
  7.8.2 Johnson & Johnson Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.8.3 Johnson & Johnson Immuno-oncology Drugs Product Introduction
  7.8.4 Johnson & Johnson Response to COVID-19 and Related Developments
7.9 Novartis International AG
  7.9.1 Novartis International AG Business Overview
  7.9.2 Novartis International AG Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.9.3 Novartis International AG Immuno-oncology Drugs Product Introduction
  7.9.4 Novartis International AG Response to COVID-19 and Related Developments
7.10 AbbVie, Inc.
  7.10.1 AbbVie, Inc. Business Overview
  7.10.2 AbbVie, Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.10.3 AbbVie, Inc. Immuno-oncology Drugs Product Introduction
  7.10.4 AbbVie, Inc. Response to COVID-19 and Related Developments
7.11 Pfizer Inc.
  7.11.1 Pfizer Inc. Business Overview
  7.11.2 Pfizer Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.11.3 Pfizer Inc. Immuno-oncology Drugs Product Introduction
  7.11.4 Pfizer Inc. Response to COVID-19 and Related Developments
7.12 Sanofi S.A.
  7.12.1 Sanofi S.A. Business Overview
  7.12.2 Sanofi S.A. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.12.3 Sanofi S.A. Immuno-oncology Drugs Product Introduction
  7.12.4 Sanofi S.A. Response to COVID-19 and Related Developments
7.13 EMD Serono, Inc.
  7.13.1 EMD Serono, Inc. Business Overview
  7.13.2 EMD Serono, Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.13.3 EMD Serono, Inc. Immuno-oncology Drugs Product Introduction
  7.13.4 EMD Serono, Inc. Response to COVID-19 and Related Developments
7.14 Gilead Sciences Inc.
  7.14.1 Gilead Sciences Inc. Business Overview
  7.14.2 Gilead Sciences Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Product Introduction
  7.14.4 Gilead Sciences Inc. Response to COVID-19 and Related Developments
7.15 Prometheus Therapeutics & Diagnostics
  7.15.1 Prometheus Therapeutics & Diagnostics Business Overview
  7.15.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Introduction
  7.15.4 Prometheus Therapeutics & Diagnostics Response to COVID-19 and Related Developments
7.16 Aduro BioTech
  7.16.1 Aduro BioTech Business Overview
  7.16.2 Aduro BioTech Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.16.3 Aduro BioTech Immuno-oncology Drugs Product Introduction
  7.16.4 Aduro BioTech Response to COVID-19 and Related Developments
7.17 Galena Biopharma
  7.17.1 Galena Biopharma Business Overview
  7.17.2 Galena Biopharma Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.17.3 Galena Biopharma Immuno-oncology Drugs Product Introduction
  7.17.4 Galena Biopharma Response to COVID-19 and Related Developments
7.18 Bavarian Nordic
  7.18.1 Bavarian Nordic Business Overview
  7.18.2 Bavarian Nordic Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.18.3 Bavarian Nordic Immuno-oncology Drugs Product Introduction
  7.18.4 Bavarian Nordic Response to COVID-19 and Related Developments
7.19 Celldex Therapeutics
  7.19.1 Celldex Therapeutics Business Overview
  7.19.2 Celldex Therapeutics Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.19.3 Celldex Therapeutics Immuno-oncology Drugs Product Introduction
  7.19.4 Celldex Therapeutics Response to COVID-19 and Related Developments
7.20 ImmunoCellular Therapeutics
  7.20.1 ImmunoCellular Therapeutics Business Overview
  7.20.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Introduction
  7.20.4 ImmunoCellular Therapeutics Response to COVID-19 and Related Developments
7.21 Incyte
  7.21.1 Incyte Business Overview
  7.21.2 Incyte Immuno-oncology Drugs Quarterly Production and Revenue, 2020
  7.21.3 Incyte Immuno-oncology Drugs Product Introduction
  7.21.4 Incyte Response to COVID-19 and Related Developments

8 SUPPLY CHAIN AND SALES CHANNELS ANALYSIS

8.1 Immuno-oncology Drugs Supply Chain Analysis
  8.1.1 Immuno-oncology Drugs Supply Chain Analysis
  8.1.2 Covid-19 Impact on Immuno-oncology Drugs Supply Chain
8.2 Distribution Channels Analysis
  8.2.1 Immuno-oncology Drugs Distribution Channels
  8.2.2 Covid-19 Impact on Immuno-oncology Drugs Distribution Channels
  8.2.3 Immuno-oncology Drugs Distributors
8.3 Immuno-oncology Drugs Customers

9 KEY FINDINGS

10 APPENDIX

10.1 About Us
10.2 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Immuno-oncology Drugs Assessment
Table 9. COVID-19 Impact: Immuno-oncology Drugs Market Trends
Table 10. COVID-19 Impact Global Immuno-oncology Drugs Market Size
Table 11. Global Immuno-oncology Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)
Table 12. Global Immuno-oncology Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)
Table 13. Global Immuno-oncology Drugs Quarterly Market Size, 2020 (US$ Million) & (K Units)
Table 14. Global Immuno-oncology Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 15. Global Immuno-oncology Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)
Table 16. Global Immuno-oncology Drugs Market Growth Drivers
Table 17. Global Immuno-oncology Drugs Market Restraints
Table 18. Global Immuno-oncology Drugs Market Opportunities
Table 19. Global Immuno-oncology Drugs Market Challenges
Table 20. Key Manufacturers Immuno-oncology Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 21. Top Manufacturers, Immuno-oncology Drugs Market Size, 2019 (K Units) & (US$ Million)
Table 22. Immuno-oncology Drugs Factory Price by Manufacturers 2020 (USD/Unit)
Table 23. Location of Key Manufacturers Immuno-oncology Drugs Manufacturing Plants
Table 24. Key Manufacturers Immuno-oncology Drugs Market Served
Table 25. Date of Key Manufacturers Enter into Immuno-oncology Drugs Market
Table 26. Key Manufacturers Immuno-oncology Drugs Product Type
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Immuno-oncology Drugs Market Size by Type, 2020, (US$ Million)
Table 29. Global Immuno-oncology Drugs Market Size by Type, 2020 (K Units)
Table 30. Global Immuno-oncology Drugs Price: by Type, 2020-2021 (USD/Unit)
Table 31. Global Immuno-oncology Drugs Market Size by Application: 2020-2021 (US$ Million)
Table 32. Global Immuno-oncology Drugs Market Size by Application, 2020-2021 (K Units)
Table 33. Global Immuno-oncology Drugs Price: by Application, 2020-2021 (USD/Unit)
Table 34. Global Immuno-oncology Drugs Market Size by Region, 2019-2021 (US$ Million)
Table 35. Global Immuno-oncology Drugs Market Size by Region, 2019-2021 (K Units)
Table 36. By Country, North America Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million)
Table 37. By Country, North America Immuno-oncology Drugs Market Size, 2019-2021 (K Units)
Table 38. US Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 39. Canada Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 41. By Country, Europe Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million)
Table 42. By Country, Europe Immuno-oncology Drugs Market Size, 2019-2021 (K Units)
Table 43. Germany Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 44. France Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 45. UK Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 46. Italy Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 48. By Region, Asia-Pacific Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million)
Table 49. By Region, Asia-Pacific Immuno-oncology Drugs Market Size, 2019-2021 (K Units)
Table 50. China Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 51. Japan Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 52. South Korea Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 53. India Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 54. ASEAN Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 55. Latin America Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 56. Middle East and Africa Immuno-oncology Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 57. Amgen, Inc Business Overview
Table 58. Amgen, Inc Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Amgen, Inc Immuno-oncology Drugs Product
Table 60. Amgen, Inc Response to COVID-19 and Related Developments
Table 61. AstraZeneca, Plc Business Overview
Table 62. AstraZeneca, Plc Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. AstraZeneca, Plc Immuno-oncology Drugs Product
Table 64. AstraZeneca, Plc Response to COVID-19 and Related Developments
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Bristol-Myers Squibb Immuno-oncology Drugs Product
Table 68. Bristol-Myers Squibb Response to COVID-19 and Related Developments
Table 69. Celgene Corporation Business Overview
Table 70. Celgene Corporation Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Celgene Corporation Immuno-oncology Drugs Product
Table 72. Celgene Corporation Response to COVID-19 and Related Developments
Table 73. Eli Lilly and Company Business Overview
Table 74. Eli Lilly and Company Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Eli Lilly and Company Immuno-oncology Drugs Product
Table 76. Eli Lilly and Company Response to COVID-19 and Related Developments
Table 77. Merck & Co. Business Overview
Table 78. Merck & Co. Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Merck & Co. Immuno-oncology Drugs Product
Table 80. Merck & Co. Response to COVID-19 and Related Developments
Table 81. Hoffmann-La Roche AG Business Overview
Table 82. Hoffmann-La Roche AG Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Hoffmann-La Roche AG Immuno-oncology Drugs Product
Table 84. Hoffmann-La Roche AG Response to COVID-19 and Related Developments
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Johnson & Johnson Immuno-oncology Drugs Product
Table 88. Johnson & Johnson Response to COVID-19 and Related Developments
Table 89. Novartis International AG Business Overview
Table 90. Novartis International AG Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Novartis International AG Immuno-oncology Drugs Product
Table 92. Novartis International AG Response to COVID-19 and Related Developments
Table 93. AbbVie, Inc. Business Overview
Table 94. AbbVie, Inc. Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. AbbVie, Inc. Immuno-oncology Drugs Product
Table 96. AbbVie, Inc. Response to COVID-19 and Related Developments
Table 97. Pfizer Inc. Business Overview
Table 98. Pfizer Inc. Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Pfizer Inc. Immuno-oncology Drugs Product
Table 100. Pfizer Inc. Response to COVID-19 and Related Developments
Table 101. Sanofi S.A. Business Overview
Table 102. Sanofi S.A. Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 103. Sanofi S.A. Immuno-oncology Drugs Product
Table 104. Sanofi S.A. Response to COVID-19 and Related Developments
Table 105. EMD Serono, Inc. Business Overview
Table 106. EMD Serono, Inc. Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 107. EMD Serono, Inc. Immuno-oncology Drugs Product
Table 108. EMD Serono, Inc. Response to COVID-19 and Related Developments
Table 109. Gilead Sciences Inc. Business Overview
Table 110. Gilead Sciences Inc. Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 111. Gilead Sciences Inc. Immuno-oncology Drugs Product
Table 112. Gilead Sciences Inc. Response to COVID-19 and Related Developments
Table 113. Prometheus Therapeutics & Diagnostics Business Overview
Table 114. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 115. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product
Table 116. Prometheus Therapeutics & Diagnostics Response to COVID-19 and Related Developments
Table 117. Aduro BioTech Business Overview
Table 118. Aduro BioTech Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 119. Aduro BioTech Immuno-oncology Drugs Product
Table 120. Aduro BioTech Response to COVID-19 and Related Developments
Table 121. Galena Biopharma Business Overview
Table 122. Galena Biopharma Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 123. Galena Biopharma Immuno-oncology Drugs Product
Table 124. Galena Biopharma Response to COVID-19 and Related Developments
Table 125. Bavarian Nordic Business Overview
Table 126. Bavarian Nordic Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 127. Bavarian Nordic Immuno-oncology Drugs Product
Table 128. Bavarian Nordic Response to COVID-19 and Related Developments
Table 129. Celldex Therapeutics Business Overview
Table 130. Celldex Therapeutics Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 131. Celldex Therapeutics Immuno-oncology Drugs Product
Table 132. Celldex Therapeutics Response to COVID-19 and Related Developments
Table 133. ImmunoCellular Therapeutics Business Overview
Table 134. ImmunoCellular Therapeutics Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 135. ImmunoCellular Therapeutics Immuno-oncology Drugs Product
Table 136. ImmunoCellular Therapeutics Response to COVID-19 and Related Developments
Table 137. Incyte Business Overview
Table 138. Incyte Immuno-oncology Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 139. Incyte Immuno-oncology Drugs Product
Table 140. Incyte Response to COVID-19 and Related Developments
Table 141. Immuno-oncology Drugs Distributors List
Table 142. Immuno-oncology Drugs Customers List
Table 143. Covid-19 Impact on Immuno-oncology Drugs Customers

List Of Figures

LIST OF FIGURES

Figure 1. Immuno-oncology Drugs Product Picture
Figure 2. Immuno-oncology Drugs Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Immuno-oncology Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Immuno-oncology Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Immuno-oncology Drugs Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Immuno-oncology Drugs Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Immuno-oncology Drugs Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Immuno-oncology Drugs Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Immuno-oncology Drugs Market Size Market Share, 2019-2021